Status:
COMPLETED
The Effect of Different Molecular Weight of HA for Carpal Tunnel Syndrome
Lead Sponsor:
Tri-Service General Hospital
Conditions:
Carpal Tunnel Syndrome
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
Recently, nerve hydrodissection is utilized to assist ultrasound-guided nerve injection and studies recommend its clinical benefit for peripheral entrapment neuropathy. Hyaluronic acid (HA) can decrea...
Detailed Description
Participants established with diagnosis of mild-to-moderate CTS will been randomly assigned to high molecular weight HA (Aragan Plus, 20 mg/2 ml, 3000kDa) or low molecular weight HA (ARTZDispo, 25 mg/...
Eligibility Criteria
Inclusion
- Age between 20-80 year-old.
- Diagnosis was confirmed using an electrophysiological study
Exclusion
- Cancer
- Coagulopathy
- Pregnancy
- Inflammation status
- Cervical radiculopathy
- Polyneuropathy, brachial plexopathy
- Thoracic outlet syndrome
- Previously undergone wrist surgery or steroid injection for CTS
Key Trial Info
Start Date :
August 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04766918
Start Date
August 1 2021
End Date
October 31 2023
Last Update
April 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tri-Service General Hospital, School of Medicine, National Defense Medical Center
Taipei, Neihu, Taiwan, 886